An announcement from Galmed Pharmaceuticals ( (GLMD) ) is now available.
On April 28, 2025, Galmed Pharmaceuticals announced the signing of a binding term sheet with Entomus s.r.o. to develop and commercialize a novel sublingual formulation of semaglutide using their proprietary Self-Emulsifying Drug Delivery System (SEDDS). This formulation aims to provide an alternative to existing injectable and oral forms of semaglutide, offering a non-invasive route that could enhance bioavailability and patient compliance. The development is significant given the growing GLP-1 market, projected to reach over $120 billion by 2030, and the potential for Galmed to expand into markets where semaglutide patents are expiring soon, such as India and Brazil.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals’ overall score is low, primarily due to the absence of revenue and continuous financial losses, which are significant risks. Technical indicators and valuation metrics do not provide enough positive signals to counteract the financial weaknesses.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company primarily focused on developing treatments for cardiometabolic diseases and gastrointestinal oncological indications. The company is actively working on expanding its product pipeline, targeting innovative candidates that align with its expertise in drug development.
YTD Price Performance: -52.71%
Average Trading Volume: 892,523
Technical Sentiment Signal: Buy
Current Market Cap: $3.55M
Learn more about GLMD stock on TipRanks’ Stock Analysis page.